A Study of YP05002 in Healthy Participants

Launched by YAOPHARMA CO., LTD. · Jul 25, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new medicine called YP05002 to see if it is safe and well-tolerated in healthy adults. The study focuses on how the body processes the medicine, its effects, and whether taking it with food makes a difference. It is an early-stage (Phase 1) study where some participants will receive the medicine and others will get a placebo (a harmless pill with no active medicine), but neither the participants nor the researchers will know who gets which until the study ends.

Adults between 18 and 65 years old who are in good health and willing to follow the study’s schedule may be eligible to join. Participants should not have any serious medical conditions, recent use of certain medications, or a history of pancreatitis or cancer (except some common skin cancers) in the past five years. If selected, participants can expect to visit the study site for tests, take the study tablets, and have their health closely monitored throughout the trial to ensure safety. This study is not yet open for enrollment but aims to gather important information for future research on weight management treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
• • 2. Healthy male and female participants aged 18-65 years (both inclusive).No restrictions on race.
• • 3. In good health as determined by the Investigator, with no clinically significant findings from medical/psychiatric history, physical examination, 12-lead ECG, vital signs measurements, clinical laboratory evaluations.
• Exclusion Criteria:
• • 1. Have evidence of any clinically significant active or chronic disease.
• • 2. Histories of using drug that affect drug absorption, distribution, metabolism, or excretion within 14 days or within 5-half-life prior to the first dose (whichever is longer); gastrointestinal disorders with impaired gastric emptying; or prolonged use of medications that directly modulate gastrointestinal motility.
• • 3. Had clinically relevant acute or chronic medical conditions or diseases that would pose a risk to participant's safety or interfere with the study assessments, as determined by the Investigator.
• • 4. Any malignancy (except basal cell carcinoma and squamous cell carcinoma of the skin) in the previous 5 years.
• • 5. Diagnosis of any type of pancreatitis.